检索结果-南通市图书馆

Productive Response of Brassica rapa *** to Application of VIUSID Agro

Journal of Agricultural Science and Technology(B) 2019年第2期9卷 103-109页

作者： Kolima Pena Calzada Dilier Olivera Viciedo Alexander Calero Juan Carlos Rodríguez bulent Kukurtcu Yanet Milagros Placenciaálvarez Alexei Castro Salas Department of Agronomy Faculty of Agricultural SciencesUniversity of Sancti Spiritus Jose Marti Perez(UNISS)Sancti Spiritus 60100Cuba School of Agricultural and Veterinarian Sciences Sao Paulo State University(UNESP)Jaboticabal 1480Sao PauloBrazil Scientific Department CatalysisS.L.Madrid 28016Spain Department of Mathematics University of Camagüey Ignacio Agramonte LoynazCamagüey 74650Cuba

In order to evaluate the effect of VIUSID agro on the yield response of a pak choi harvest,a randomised block experiment was designed with four treatments and three *** treatments were dosages of 0.1,0.2 and 0.3 L/ha and one *** number of leaves per plant and the fresh and dry mass of the plant were *** addition,growth indexes were evaluated,such as relative growth rate,active growth rate,harvest index and agricultural *** number of leaves per plant was significantly greater at 35 days after sowing(das)for 0.2 L/ha and 0.3 L/ha treatments,with increases of 15.0%and 14.17%relative to the *** plant length and fresh mass at the final evaluation,the treatments using higher dosages produced the best *** the active growth rate,the 0.2 L/ha dosage produced the best effects,and regarding relative growth rate,the 0.2 L/ha and 0.3 L/ha dosages produced the best results relative to the *** harvest index did not benefit from the used dosages,while a higher agricultural yield was achieved using the 0.2 L/ha and 0.3 L/ha dosages at 18.03%and 12.88%compared to the ***,VIUSID agro positively influenced the yield behaviour of pak choi.

关键词： VIUSID agro pak choi amino acids vegetables.

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

帕博利珠单抗治疗伴脑转移NSCLC患者的一项非随机、开放Ⅱ期试验的长期随访结果和生物标志物分析

引用

中国肺癌杂志 2021年第9期24卷 I0007-I0016页

作者： Sarah B GOLDBERG Kurt A SCHALPER Scott N GETTINGER Amit MAHAJAN Roy S HERBST Anne C CHANG Rogerio LILENBAUM Frederick H WILSON Sacit bulent OMAY James B YU Lucia JILAVEANU Thuy TRAN Kira PAVLIK Elin ROWEN Heather GERRSH Annette KOMLO Richa GUPTA Hailey WYATT Matthew RIBEIRO Yuval KLUGER Geyu ZHOU Wei WEI Veronica L CHANG Harriet M KLUGER 董晓荣(翻译/校对) Department of Medicine(Medical Oncology) Yale School of MedicineNew HavenCTUSA Department of Pathology Yale School of MedicineNew HavenCTUSA Department of Radiology Yale School of MedicineNew HavenCTUSA Department of Neurosurgery Yale School of MedicineNew HavenCTUSA Department of Therapeutic Radiology Yale School of MedicineNew HavenCTUSA Interdepartmental Program in Computational Biology and Bioinformatics Yale School of MedicineNew HavenCTUSA Department of Biostatistics Yale School of Public HealthNew HavenCTUSA 华中科技大学同济医学院附属协和医院胸部肿瘤科

背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(ce... 详细信息

背景与目的我们开展了一项帕博利珠单抗用于伴未治疗脑转移的非小细胞肺癌(non-small cell lung cancer,NSCLC)或黑色素瘤患者的疗效和安全性的II期试验,旨在评估程序性死亡受体1(programmed cell death 1,PD-1)抑制剂在中枢神经系统(central nervous system,CNS)中的疗效。中期结果已发表,现报道对NSCLC队列的更新分析结果。方法这是一项开放性、单中心、II期试验。纳入标准:年龄≥18岁,诊断为晚期NSCLC并伴有≥1个5 mm-20 mm脑转移病灶,既往从未治疗或之前放疗后进展,无神经系统症状,不需要激素治疗且美国东部肿瘤协作组(Eastern Cooperative Oncology Group,ECOG)<2分。患者每2周接受一次帕博利珠单抗(10 mg/kg)治疗。队列1为程序性死亡配体1(programmed cell death ligand 1,PD-L1)≥1%的患者,队列2为PD-L1<1%或未评估的患者。主要终点是脑转移患者缓解比例。所有经治患者均纳入疗效与安全性终点的分析。该研究已结束入组,并于***登记注册,注册号为NCT02085070。结果2014年3月31日-2018年5月21日,共42例患者接受治疗。中位随访时间为8.3个月(IQR:4.5个月-26.2个月)。队列1的37例患者中11例有脑转移缓解[29.7%(95%CI:15.9%-47.0%)]。队列2未观察到缓解。治疗相关的3级-4级不良事件(adverse events,AEs)包括2例肺炎、1例全身症状、1例结肠炎、1例肾上腺皮质功能不全、1例高血糖症和1例低钾血症。6例(14%)患者发生了治疗相关的严重不良事件,包括肺炎、急性肾损伤、低钾血症和肾上腺皮质功能不全。没有观察到治疗相关死亡病例。结论帕博利珠单抗治疗PD-L1≥1%的NSCLC伴脑转移患者有效,且对所有纳入的未经治疗的脑转移患者安全。需要进一步探索免疫治疗用于NSCLC合并CNS转移。

关键词：非小细胞肺癌脑转移免疫治疗帕博利珠单抗

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

What is the impact of capsule endoscopy in the long term period?

引用

World Journal of Gastrointestinal Endoscopy 2016年第7期8卷 344-348页

作者： Asli Ormeci Filiz Akyuz bulent Baran Suut Gokturk Tugrul Ormeci Binnur Pinarbasi Ozlem Mutluay Soyer Sami Evirgen Umit Akyuz Cetin Karaca Kadir Demir Sabahattin Kaymakoglu Fatih Besisik Division of Gastroenterohepatology Department of Internal Medicine Istanbul Faculty of Medicine Istanbul University Department of Radiology Medipol University Department of Gastroenterology Yeditepe Univer-sity

AIM: To assess the clinical impact of capsule endoscopy(CE) in the long-term follow-up period in patients with obscure gastrointestinal bleeding(OGIB). METHODS: One hundred and forty-one patients who applied CE for OGIB between 2009 and 2012 were retrospectively analyzed, and this cohort was then questioned prospectively. Demographic data of the patients were determined via the presence of comorbid diseases, use of non-steroidal anti-inflammatory drugs anticoagulant-antiaggregant agents, previous diagnostic tests for bleeding episodes, CE findings, laboratory tests and ***: CE was performed on 141 patients becauseof OGIB. The capsule was retained in the upper gastrointestinal(GI) system in two of the patients, thus video monitoring was not achieved. There were 139 patients [62% male, median age: 72 years(range: 13-93 years) and a median follow-up duration: 32 mo(range: 6-82 mo)]. The overall diagnostic yield of CE was 84.9%. Rebleeding was determined in 40.3%(56/139) of the patients. The rebleeding rates of patients with positive and negative capsule results at the end of the follow-up were 46.6%(55/118) and 4.8%(1/21), respectively. In the multivariate analysis, usage of NSAIDs, anticoagulant-antiaggregant therapies(OR = 5.8; 95%CI: 1.86-18.27) and vascular ectasia(OR = 6.02; 95%CI: 2.568-14.146) in CE were detected as independent predictors of rebleeding. In the univariate analysis, advanced age, comorbidity, and overt bleeding were detected as predictors of ***: CE is a reliable method in the diagnosis of obscure GI bleeding. Negative CE correlated with a significantly lower rebleeding risk in the long-term follow-up period.

关键词： Capsule endoscopy Small bowel Obscure gastrointestinal bleeding Rebleeding

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A candidate identification questionnaire for postmenopausal osteoporosis patients switched from daily or weekly bisphosphonate to once-monthly ibandronate: An open, prospective, multicenter study—BONCURE study

引用

Health 2013年第7期5卷 30-40页

作者： Yesim Gokce Kutsal Nurten Eskiyurt Jale Irdesel Vesile Sepici Hatice Ugurlu Yesim Kirazli Fusun Ardic Mirko Korsic Tonko Vlak Mane Grlickov Snezana Markovic Temelkova Miroslav Lazarov Nada Pilipovic Vera Popovic Aleksandar Dimic Branka Kovacev Dorina Ruci Argjend Tafaj Elma Kucukalic-Selimovic Dijana Avdic Hajrija Seleskovic Snjezana Pejicic bulent Butun Gulseren Akyuz Lale Cerrahoglu Omer Faruk Sendur Peyman Yalcin Sema Oncel Merih Saridogan Tunay Sarpel Mehmet Tosun Kazim Senel Savas Gursoy Ferhan Canturk Huseyin Demir Blazenka Miskic Dalibor Krpan Franjo Skreb Simeon Grazio Zeljka Crncevic-Orlic Fatih Ozdener Hakan Oncel Clinic for Orthopaedic Surgery Clinical Centre Vodnjansk Skopje Macedonia Clinic of Endocrinology Diabetes and Metabolic Disorders Skopje Macedonia Clinic of Rheumatology Clinical Centre Skopje Macedonia Clinical Center of Vojvodina Novi Sad Serbia Clinical Center Banja Luka Bosnia and Herzegovina Clinical Hospital Centre Split Croatia Department of PMR Cerrahpasa School of Medicine Istanbul University Istanbul Turkey Department of PMR Clinical Hospital Center Rijeka Rijeka Croatia Department of PMR Dr. Josip Bencevic General Hospital Slavonski Brod Croatia Department of PMR Istanbul School of Medicine Istanbul University Istanbul Turkey Department of PMR Polyclinic for Internal Medicine Zagreb Croatia Department of PMR School of Medicine Adnan Menderes University Aydin Turkey Department of PMR School of Medicine Akdeniz University Ankara Turkey Department of PMR School of Medicine Ankara University Ankara Turkey Department of PMR School of Medicine Ataturk University Erzurum Turkey Department of PMR School of Medicine Celal Bayar University Manisa Turkey Department of PMR School of Medicine Cukurova University Adana Turkey Department of PMR School of Medicine Dokuz Eylul University Izmir Turkey Department of PMR School of Medicine Ege University Izmir Turkey Department of PMR School of Medicine Erciyes University Kayseri Turkey Department of PMR School of Medicine Gazi University Ankara Turkey Department of PMR School of Medicine Gaziantep University Gaziantep Turkey Department of PMR School of Medicine Hacettepe University Ankara Turkey Department of PMR School of Medicine Karadeniz Technical University Trabzon Turkey Department of PMR School of Medicine Marmara University Istanbul Turkey Department of PMR School of Medicine Ondokuz Mayis University Samsun Turkey Department of PMR School of Medicine Pamukkale University Denizli Turkey Department of PMR School of Medicine Selcuk University Konya Turkey Department

A candidate identification questionnaire (CIQ) was tested to determine its predictive value for patient-reported satisfaction in patients switched from once-weekly or once-daily treatment with a bisphosphonate to once-monthly dosing. This was a prospective, open-label, multicenter international study in patients with postmenopausal osteoporosis who had been receiving once-daily or once-weekly alendronate or risendronate for at least 3 months. Patients completed a CIQ, then commenced 150 mg monthly ibandronate for 6 months. Patients completed the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-QTM) at baseline for 6 months. Scores were converted to composite satisfaction scores (CSS, scale 0-100). Totally 677 patients completed a CIQ, 645 were enrolled in the treatment phase and comprised the intent-to-treat (ITT) population, and 630 completed the study. In the ITT population, 68.1% patients answered “yes” to one or more CIQ questions. OPSAT-Q scores increased for the convenience, quality of life and overall satisfaction domains (p scores for the side effects domains were significant (p < 0.001) in the CIQ “yes” group, but not for the degree of bother (decrease in mean of 0.1 points, p = 0.50) or duration (no change, p = 0.84) of non-gastrointestinal side effects. Of 638 patients who completed the preference questionnaire, 93.0% of patients preferred the once-monthly dosing schedule and 563 patients (90.7%) found it more convenient. The most common adverse events were dyspepsia (1.9%), nausea (1.1%), and upper abdominal pain (0.9%). Patients are likely to prefer treatment with monthly ibandronate to a weekly or monthly bisphosphonate irrespective of their stated preference before switching treatment.

关键词： Bisphosphonate Compliance Ibandronate Postmenopausal Osteoporosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：